011000.KS Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:30):

Stats
Dzisiejszy wolumen	153 015
Średni wolumen	652 340
Kapitalizacja rynkowa	193.59B
EPS	KRW0 ( 2023-09-30 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	-3.57
ATR14	KRW4.47 (0.18%)

Wolumen Korelacja

Długi: 0.09 (neutral)

Krótki: 0.66 (moderate)

Signal:(49.789) Neutral

GeneOne Life Science, Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GeneOne Life Science, Korelacja - Waluta/Towar

0.30
( neutral )

0.26
( neutral )

0.28
( neutral )

-0.31
( neutral )

GeneOne Life Science, Finanse

Annual	2023
Przychody:	KRW40.20B
Zysk brutto:	KRW-14.98B (-37.27 %)
EPS:	KRW-1 000.23

FY	2023
Przychody:	KRW40.20B
Zysk brutto:	KRW-14.98B (-37.27 %)
EPS:	KRW-1 000.23

FY	2022
Przychody:	KRW48.72B
Zysk brutto:	KRW9.34B (19.16 %)
EPS:	KRW-492.35

FY	2021
Przychody:	KRW38.70B
Zysk brutto:	KRW8.76B (22.63 %)
EPS:	KRW-218.13

Financial Reports:

No articles found.

GeneOne Life Science,

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.